ClinicalTrials.gg
CompletedNCT04552600Updated Dec 12, 2025

Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.

A Phase 1/2 interventional study of Nuvastatic and Placebo in Diabetic Retinopathy, sponsored by Natureceuticals Sdn Bhd. Completed at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Natureceuticals Sdn Bhd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Sep 2019, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Diabetic Retinopathy with a site in India — none open to participants now, none under way, none of them phase 3. Diabetic Retinopathy · India.

Started
2019
the only one that year
Phase 1/2
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Natureceuticals Sdn Bhd

Among the 10 studies in Diabetic Retinopathy with a site in India, this one is the only one that started in 2019, is the only one in phase 1/2, and was the 9th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

None of the 10 studies in Diabetic Retinopathy with a site in India is open now. The open studies under Diabetic Retinopathy, anywhere →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Diabetic Retinopathy with a site in India as a file.
02

Study summary

Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults. An ideal adjunctive agent for treating DR hence should be polymorphic and possess antiangiogenic, neuroprotective, anti-inflammatory, anti-oxidant as well as anti-ischaemic properties.Natureceuticals Sdn Bhd assessed the efficacy of core ingredient of Nuvastatic™, Lanctos 75™ for the treatment and management of the diabetic retinopathic condition.

Read the detailed description

Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults. During progression of DR, patients can develop diabetic macular edema (DME), which is characterized by the thickening of the macula caused by the breakdown of the blood-retinal barrier and consequent retinal vascular hyperpermeability. In 2010, the global prevalence of DR among adults with diabetes mellitus aged 20-79 years was estimated to be 34.6% for any DR and 6.81% for DME. DME is the leading cause of vision loss among patients with DR. It is associated with the type of diabetes, and increases with the duration and severity of disease. Other significant risk factors common to DR and DME include hyperglycemia and hypertension. DME negatively impacts patients' health-related quality of life and represents an economic burden due to the increased use of healthcare resources by affected patients.

In DR, which is a complex multifactorial disease, basically the retinal neovascularization occurs with the disturbance of physiological angiogenesis due to creation of hypoxic condition, which induces the oxygen demand in the retina (Roth, 1977; Smith et al., 1994; Chen and Smith, 2007). Consequently, in response to induced hypoxia, excessive production and over expression of VEGF and other pro-angiogenic factors take place in the retina. This ultimately induces the situation so called "pathological neovascularization" (Aiello et al., 1994; Folkman, 2006). Retinal ischemia is a common precursor to vitreal neovascularization in retinal diseases (Tolentino and Adamis, 1998) and is strongly associated with a local inflammatory response in the ischemic retina (Barouch et al., 2000).

While there is no curative treatment available for DME, laser photocoagulation represents an effective treatment to preserve vision. However, this treatment modality is limited by its inability to restore vision once it has been lost. The current standard of care for DME includes intravitreal anti-vascular endothelial growth factor (VEGF) therapeutics and corticosteroids. Clinical studies have confirmed that monthly intravitreal treatment with the anti-VEGF treatment can improve vision, with up to 45% of patients gaining ≥ 15 letters in best-corrected visual acuity (BCVA) after 24 months. Similar improvements were found after treatment with the anti-VEGF antibodies. Despite the proven efficacy of VEGF inhibitors, the requirement of frequent injections causes a high rate of treatment discontinuation among patients with DME and represents a major limitation.

Thus, current pharmacological treatments target single pathogenic processes with a narrow therapeutic range and may cause adverse side effects leading to undesired systemic effects. The presence of potential side effects and the significant proportion of patients who do not respond to treatment suggest that there remains a need for the development of improved therapies for DR and DME.

An ideal adjunctive agent for treating DR hence should be polymorphic and possess antiangiogenic, neuroprotective, anti-inflammatory, anti-oxidant as well as anti-ischaemic properties.

We have assessed the efficacy of core ingredient of Nuvastatic™, Lanctos 75™ for the treatment and management of the diabetic retinopathic condition. These scientific studies have shown that the standardized extract of O. stamineus (Lanctos 75™) in mediates antiangiogenic actions via blocking VEGF pathway. We demonstrated the potent antiangiogenic activity of the standardized extract of O. stamineus and prevention activity of the extract against human breast tumor in xenograft model. In addition, it is reported that, the extract was found to specifically inhibit VEGF expression and VEGFR phosphorylation known to be up-regulated in new blood vessel formation which in turn leads to suppression of vascularization and thereby ultimately the growth of tumor will be affected. Rosmarinic acid present in the extract could be involved in cell cycle arrest in the G0/G1 and G1/S phases, exhibiting an anti-proliferative effect of thus suggesting that the proliferative vascular diseases including retinopathy might be the potential target for the pharmacological application of rosmarinic acid. Also, the key active ingredients in the extract are rosmarinic acid mainly, and sinensetin, eupatorin and betulinic acid, which are readily absorbed into the plasma and exert that conferred the synergistic pharmacological response such as anti-inflammatory, antioxidant, analgesic and neuroprotective effects.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Type-2 Diabetes mellius (NIDDM) patients of both genders aged 18-65 years.

      • Able and willing to provide written .
      • Documented diagnosis of Type 2 diabetes mellitus a glycosylated (HbA1c) of ≤ 12.0% at screening.
      • Patients preferably on oral medications for DM.
      • Meets specific ocular criteria for the study eye including but not limited to, the presence of non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) in the study eye at screening with NPDR level 47 or level 53, as determined by the central reading center (CRC) by using the DR severity scale (DRSS), for which treatment can be deferred for at least 4 weeks after Day 1 visit.
      • Media clarity, pupillary dilation, and subject cooperation sufficient to obtain adequate assessments. (Subject has early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) letter score ≤ 73 (Snellen 20/40) and ≥ 24 (Snellen 20/320) at screening visit).
      • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.

Study Eye Inclusion Criteria

  • Best corrected E-ETDRS visual acuity letter score ≥74 (i.e.20/32 or better) within 8 days of randomization.
  • On clinical exam, definite retinal thickening due to DME within 3000 μm of the center of the macula but not involving the central subfield.
  • Thickened non-central macular subfields on spectral domain OCT macular map that meet either of the following criteria:

    1. At least two non-central macular subfields with OCT thickness above threshold (average normal + 2 SD) from DRCR.net approved spectral domain OCT machines- see below.
    2. At least one non-central macular subfield with OCT thickness at least 15 μm above threshold (average normal + 2 SD) from DRCR.net approved spectral domain OCT machines-see DRCR.net procedures manual for threshold details.
  • Central subfield thickness \<250 microns obtained by one of the following DRCR.net approved spectral domain OCT machines:

    1. Zeiss Cirrus
    2. Heidelberg Spectralis
    3. Optovue RTVue
  • Media clarity, pupillary dilation, and study participant cooperation sufficient for adequate OCT and fundus photographs.
  • If the study participant is on multiple ocular drops, investigator believes that study participant can be compliant with a multi-drop regimen.

Exclusion criteria

Exclusion Criteria:

  • Insulin dependent Diabetes mellitus (IDDM or T1DM) patients.
  • Any condition that would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease or glycemic control).
  • History of myocardial infarction or other acute cardiac event.
  • History of chronic renal failure requiring dialysis or kidney transplant.
  • Prior participation in any clinical study.
  • Treatment with any study drug within 30 days of screening.
  • Known allergy to study product.
  • Treatment with specific prohibited medications or therapy beginning 4 weeks prior to screening and throughout the duration of the study.
  • Subject with macular edema considered to be due to a cause other than DME, decrease in BCVA due to causes other than DME, significant macular ischemia, any other ocular disease that may cause substantial reduction in BCVA, active peri-ocular or ocular infection.
  • Subject with an history of following within 3 months prior to Day 1: non-infectious uveitis, high myopia (-8 diopter or more correction), pars plana vitrectomy, any ocular surgery, prior IVT, subtenon, or periocular, non-sustained release, therapy, uncontrolled glaucoma,
  • History of systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization.
  • Any laboratory abnormalities at screening.
  • Male subjects who are not surgically sterile and are not willing to practice a medically accepted method of with their female partner of from screening through 30 days following completion of the study
  • Female subjects of childbearing potential who are not willing to practice a medically accepted method of birth control with their non-surgically sterile male sexual partner from screening through 30 days following completion of the study
  • Female subjects who are pregnant or lactating.
  • Subject has media clarity, papillary constriction (i.e., senile miosis), or subject lacks cooperation that would interfere with any study procedures, evaluations or interpretation of data.
  • Cataract surgery performed within 6 months prior to screening or planned during the trial; or any additional eye disease in the study eye that, in the opinion of the investigator, could compromise or alter visual acuity during the course of the study (e.g. vein occlusion, uncontrolled intraocular pressure (IOP) >24 mmHg on optimal medical treatment, glaucoma with visual field loss, uveitis or other ocular inflammatory disease, vitreomacular traction, monocular vision, history of ischemic optic neuropathy, or genetic disorders such as retinitis pigmentosa)
  • Active center-involved DME (CI-DME) on clinical examination and Optical Coherence Tomography (OCT) central subfield thickness in the study eye above 300 μm as measured by Optovue OCT or above 320 μm as measured by Heidelberg OCT
  • Anterior segment and vitreous abnormalities in the study eye that would compromise the adequate assessment of the best corrected visual acuity or an adequate examination of the posterior pole
  • Evidence of neovascularization on clinical examination including active neovascularization of the iris (small iris tufts are not an exclusion) or angle neovascularization in the study eye, ruled out by gonioscopy (documented in the last 4 weeks before screening or performed at screening)
  • Prior pan-retinal photocoagulation (defined as ≥ 100 burns placed previously outside of the posterior pole) in the study eye
  • History of DME or DR treatment with macular laser within 3 months prior to screening, or intraocular injections of medication within 6 months prior to screening, and no more than 4 prior intraocular injections in the study eye at any time in the past
  • Patients treated with Monoamine Oxidase (MAO) inhibitors or drugs that may have potential side effects due to MAO inhibition
  • Current or planned, during the trial, use of medications known to be toxic to the retina, lens or optic nerve, or cause vision loss
  • Patients who must or wish to continue the intake of other restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Estimated (eGFR) \< 60 mL/min/1.73m2 calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening, or where the investigator expects filtration rate is likely to drop below 60 mL/min/1.73m2 during the trial
  • (ALT) or aspartate transaminase (AST) greater than 2.0-fold the , or total > 1.5x upper limit of normal.
  • Uncontrolled arterial hypertension defined as a single measurement of systolic blood pressure >180 mmHg, or two consecutive measurements of systolic blood pressure > 160 mmHg and/or diastolic blood pressure >100 mmHg on optimal medical regimen at screening. If blood pressure is brought to ≤ 160/100 mmHg by antihypertensive treatment until randomization, individual can become eligible.
  • Wolff-Parkinson-White Syndrome, baseline > 450 ms, family history of long QT, or on medication prolonging QT time at screening or planned initiation during the trial
  • Diagnosis of a serious or unstable systemic or eye disease and other conditions that, in the clinical judgment of the investigator, are likely to interfere with the analyses of safety and efficacy in this study. Patients with an expected of less than 2 years are also excluded.
  • Active known or suspected chronic or relevant acute infections, such as (Human Immunodeficiency Virus)\viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will be performed during screening. Patients with a positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active infection.
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable study participant or unlikely to complete the trial
  • Known to any component of the trial drug and/or allergy to fluorescein dye
  • Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned during the trial, e.g. hip replacement
  • Currently enrolled in another investigational drug trial, or less than 30 days or 5 times half-life of the investigational drug, whichever is longer, since ending another investigational drug trial from the screening visit in this trial or receiving other investigational treatment(s); patients participating in a purely observational trial will not be excluded.
  • Previous randomization in this trial
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Any other clinical condition that, in the opinion of the investigator, would jeopardize patient safety while participating in this clinical trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    NuvastaticTM 1000 mg

    NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.

    Drug: Nuvastatic

  • Active comparator
    Placebo

    NuvastaticTM (without active) will be given orally, three times per day for 12 months

    Other: Placebo

Interventions

  • DrugNuvastatic

    Phase 1b Interventional, multi-centered, double-masked, randomized

    Also known as: Lanctos 75 standardized Orthosiphon Stamineus Extract

  • OtherPlacebo

    Phase 1b Interventional, multi-centered, double-masked, randomized

06

What researchers measure

Primary outcomes

  1. To evaluate efficacy of Nuvastatic - Retinal Thickness

    Central Subfield Retinal Thickness

    Time frame: 12 months

  2. To evaluate efficacy of Nuvastatic - protein biomarkers

    protein biomarkers

    Time frame: 12 months

  3. To evaluate safety of Nuvastatic - Letter Score

    Visual Acuity Letter Score

    Time frame: 12 months

Secondary outcomes

  1. To evaluate short-term visual outcomes on severity

    effect of IP on severity of DR

    Time frame: 12 months

  2. To evaluate short-term visual outcomes on zone diagnosis

    zone diagnosis

    Time frame: 12 months

  3. To evaluate short-term visual outcomes on DRSS

    visual improvement DRSS

    Time frame: 12 months

07

Study locations

1 site
  • Fifepoint Multispeciality Hospital Pvt. Ltd.
    Pune, Maharashtra 411057, India
08

References and documents

Individual participant data

Plan to share: Yes — Requested information by institutional researcher

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Completed study

Access criteria: Institutional Researcher

Data sharing details ↗ · nature-ceuticals.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Aug 2022, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2020
First posted
Sep 17, 2020
StartActual
Sep 1, 2019
Primary completionActual
Aug 10, 2022
CompletionActual
Aug 10, 2022
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04552600
Collaborators
Ministry of Agriculture, Malaysia, Quest International University, Malaysia., Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, Universiti Sains Malaysia
Responsible party
Sponsor
First posted
Sep 17, 2020
Start date
Sep 1, 2019
Primary completion
Aug 10, 2022
Completion
Aug 10, 2022
Last update
Dec 12, 2025

Study contacts

Aman Shah Abdul Majid, Ph.D.
principal investigator · Quest International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion